Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

154 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Eligibility Leukemia, Myeloid NCT00512083

- 10/01/18 - 1 modulo, 2 itemgroups, 9 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00512083

On-Study - Acute Myeloid Leukemia (AML) - On-Study Form - Previously Untreated Patients - 2019404v4.0 - Acute Myeloid Leukemia (AML) - On-Study Form - Previously Untreated Patients

- 27/09/21 - 1 modulo, 4 itemgroups, 32 elementi, 1 linguaggio
Itemgroups: CRF Header, AML: Form Administration, AML: Disease Description, Comments
Acute Myeloid Leukemia (AML) - On-Study Form - Previously Untreated Patients Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8D071CA6-C045-F391-E040-BB89AD4376C0

Daunorubicin Acute Myeloid Leukemia NCT02140242 - Adverse events and Death sheet

- 20/09/21 - 12 moduli, 4 itemgroups, 35 elementi, 1 linguaggio
Itemgroups: Adverse Events, Adverse Events specification, Death Sheet, Comments
Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia <=60 Years. See further details on: https://www.clinicaltrials.gov/ct2/show/NCT02140242 Principal Investigator: PD Dr. med. Christoph Röllig, MSc Source:PD Dr. med. Christoph Röllig, MSc Universitätsklinikum Dresden

Visit 1 - Medical History

6 itemgroups 47 elementi

Visit Registration/Randomization I

5 itemgroups 20 elementi

Visit 13 (End of Study)

20 itemgroups 182 elementi

Drop out Sheet and visit

15 itemgroups 90 elementi

Visit 7 (Day 15 Induction I)

10 itemgroups 87 elementi

Visit 8 (before Day 1 Induction II)

9 itemgroups 123 elementi

Leukemia Daunorubicin Cytarabine Oblimersen NCT00085124 CALGB - Cytogenetics

- 20/09/21 - 1 modulo, 1 ItemGroup, 25 elementi, 1 linguaggio
ItemGroup: Cytogenetics
CALGB: CYTOGENETICS REFERRAL FORM NCT00085124 Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B229EF62-6ADF-5120-E034-0003BA12F5E7

Eligibility Acute Myeloid Leukemia NCT01382147

- 20/09/21 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01382147

Eligibility Myelogenous Leukemia, Acute NCT00130702

- 20/09/21 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00130702

Eligibility Acute Leukemia NCT01020175

- 20/09/21 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01020175

Eligibility NCT00373373 Acute Myeloid Leukemia - Eligibility

- 20/09/21 - 1 modulo, 2 itemgroups, 28 elementi, 2 lingue
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00373373

E2906 Abbreviated Comprehensive Geriatric Assessment Battery NCT01041703

- 20/09/21 - 1 modulo, 13 itemgroups, 64 elementi, 1 linguaggio
Itemgroups: Header Module, On Treatment Report Period, Data amendment, Assessment Date, Mini Mental Examination Section, GDS, ADL, MOS Social Support Survey - Emotional/Informational Support, MOS Social Support Survey - Tangible support, Comorbidity Questionnaire, Comorbidity Questionnaire1, Medications/Sexual Function, Weight
E2906 Abbreviated Comprehensive Geriatric Assessment Battery NCT01041703 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7586A704-3044-A522-E040-BB89AD4359F8

Eligibility Acute Myeloid Leukemia NCT02034227

- 20/09/21 - 1 modulo, 2 itemgroups, 21 elementi, 1 linguaggio
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia; ODM derived from: http://clinicaltrials.gov/show/NCT02034227

Treatment Form - Allogeneic Transplant NCT00049517

- 20/09/21 - 1 modulo, 8 itemgroups, 33 elementi, 1 linguaggio
Itemgroups: ECOG clinical trial administrative data, Vital Status, Transplant Conditioning Regimen, Donor Information, Allogeneic Transplant, Transfusions, Comments, CCRR MODULE
Treatment Form - Allogeneic Transplant NCT00049517 Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A727E9EC-B147-2F86-E034-0003BA0B1A09

TX5

- 20/09/21 - 1 modulo, 19 itemgroups, 46 elementi, 1 linguaggio
Itemgroups: Header module, Record the highest grade of toxicity diagnosed since the previous evaluation. If this is the first evaluation, record the highest toxicity diagnosed since day 0. The toxicity grades are based on the NCI CTCAE Version 3.0., Allergy/Immunologic toxicity, GI toxicity, Renal toxicity, Hemorrhagic toxicity, Cardiovascular toxicity, Neurologic toxicity, Coagulation toxicity, Vascular toxicity, Pulmonary toxicity, Hepatic toxicity, Did the patient develop any of the following clinical sugns/symptoms of abnormal liver function during this assessment period, Indicated the etiology of the abnormal liver function, VOD, GVHD, Infection, Other, Unknown
TX5 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF1AAC43-4B80-4030-E034-0003BA3F9857

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial